JMP Securities Reiterates Market Outperform on Integra Lifesciences, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly has reiterated a Market Outperform rating on Integra Lifesciences (NASDAQ:IART) and maintained a $65 price target.
May 26, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst David Turkaly reiterated a Market Outperform rating on Integra Lifesciences (NASDAQ:IART) and maintained a $65 price target.
The reiteration of the Market Outperform rating and maintenance of the $65 price target by JMP Securities analyst David Turkaly indicates a positive outlook for Integra Lifesciences. This news is likely to have a positive short-term impact on the stock price, as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100